Stockscreener 앱 받기
0.7816
1.23%
-0.0097
시간 외 거래:
.78
-0.0016
-0.20%
전일 마감가:
$0.7913
열려 있는:
$0.8
하루 거래량:
336.47K
Relative Volume:
0.42
시가총액:
$66.86M
수익:
-
순이익/손실:
$-50.21M
주가수익비율:
-0.4102
EPS:
-1.9053
순현금흐름:
$-16.61M
1주 성능:
-7.39%
1개월 성능:
-19.52%
6개월 성능:
-49.57%
1년 성능:
-46.47%
1일 변동 폭
$0.76
$0.83
1주일 범위
$0.7577
$0.9321
52주 변동 폭
$0.7577
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
명칭
Rein Therapeutics Inc
전화
(737) 802-1989
주소
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.7816 | 67.69M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2017-07-24 | 개시 | BofA/Merrill | Buy |
| 2017-07-24 | 개시 | Jefferies | Buy |
| 2017-07-24 | 개시 | William Blair | Outperform |
Rein Therapeutics Inc 주식(RNTX)의 최신 뉴스
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNTX|Rein Therapeutics Inc|Price:0.791|Chg%:-0.009 - TradingKey
Rein Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNTX - TradingView
Rein Therapeutics (RNTX) Proxy filing Summary - Quartr
Rein Therapeutics (RNTX) Q4 2025 earnings summary - Quartr
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Rein Therapeutics Shareholders Approve Governance and Stock Changes - TipRanks
Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com South Africa
Rein Therapeutics expands phase 2 IPF trial to Germany - Investing.com
Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial - marketscreener.com
Rein Therapeutics expects initial lung-trial data in 2H 2026 - Stock Titan
Rein Therapeutics Price Target Announced at $4.00/Share by Maxim Group - Moomoo
Rein Therapeutics (RNTX) Gains Buy Rating and $4 Price Target fr - GuruFocus
RNTX Initiates Coverage On by Maxim Group -- Rating Set to Buy - GuruFocus
Rein Therapeutics (RNTX) AGM 2026 Summary - Quartr
Transcript : Rein Therapeutics Inc.Shareholder/Analyst Call - marketscreener.com
RNTX: All agenda items, including director elections and share authorization, were approved - TradingView
RNTX: All agenda items, including director elections and share increase, were approved - TradingView
Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support LevelMcClellan Summation - DonanımHaber
Price to sales forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Enterprise value to EBITDA forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Enterprise value to revenue forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Price to earnings forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Price to earnings forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Price to sales forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Enterprise value to EBIT forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management Improves - dars.gov.et
RNTXRein Therapeutics Inc Latest SEC Filings - Finviz
Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rein Therapeutics Inc.(NasdaqCM: RNTX) added to Russell 3000E Value Benchmark - marketscreener.com
Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX) - TradingView
RNTX Forecast — Price Target — Prediction for 2027 - TradingView
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrower‑than‑expected loss as clinical pipeline advances - dars.gov.et
Rein Therapeutics Inc (RNTX) Institutional Confidence - TradingKey
Rein Therapeutics (RNTX) Surges 5.87% as Stock Tests Key Resistance at $0.97Sweep Order Flow - DonanımHaber
RNTX Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionFinal Results - dars.gov.et
Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance
Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com - Investing.com Nigeria
Rein Therapeutics (RNTX) Slips 1.6% as Stock Tests Key Support at $0.89Small Cap Breakouts - newsline.com
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherPost-Earnings Reaction - newsline.com
Rein Therapeutics enrolls 16 patients in lung fibrosis trial - Investing.com
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan
Rein Therapeutics Inc (RNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):